Final Notes
Impression
Patient has maintained hemodynamic and clinical improvements seen with initial Remodulin treatment 6 months after transitioning to Orenitram; her hemodynamic parameters have not significantly changed from baseline, and she remains at low-risk status.
Treatment Plan
Continue to titrate Orenitram as needed while monitoring for tolerability and clinical response.